NCI-MATCH Arms N & P: Phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss

F. Janku
The University of Texas MD Anderson Cancer Center

O. Jegede
Dana Farber Cancer Institute

S. L. Puhalla
The University of Pittsburgh

F. Meric-Bernstam
The University of Texas MD Anderson Cancer Center

Recommended Citation
https://jdc.jefferson.edu/medoncfp/113

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Medical Oncology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Authors

This abstract is available at Jefferson Digital Commons: https://jdc.jefferson.edu/medoncfp/113
Background: The NCI-MATCH trial is the largest national study (1173 sites) for pts with relapsed/refractory solid tumors, lymphomas and myeloma, which assigns targeted therapies based on individual tumor molecular alterations detected using the adapted Oncomine AmpliSeq panel (143 genes) and immunohistochemistry (IHC). We hypothesized that patients with PTEN-deficient cancers enrolled to Arms N and P may benefit from treatment with the PI3K beta-selective inhibitor GSK2636771.

Methods: Eligibility: relapsed/refractory ca, good end-organ function, and ECOG PS ≤3. Pts were screened for molecular alterations by centralized testing on fresh tumor biopsy and had deleterious PTEN mut/del without loss of expression (Arm N) or complete loss of cytoplasmic and nuclear PTEN staining on IHC (Arm P), and no other aberrations activating the PI3K/MTOR and MAPK pathways (mut in PIK3CA, PIK3R1, BRAF, KRAS, AKT1, TSC1/2, mTOR, RHEB, NF2, NRAS, HRAS). Pts received GSK2636771 400mg/day (28-days cycles). RECIST 1.1 overall response rate (ORR) was the primary endpoint.

Results: Of 59 enrolled pts, 56 were eligible and received treatment. Of 22 pts with PTEN mut/del (Arm N: 6 uterine, 2 breast, 2 prostate, 2 head/neck ca, 10 other), all are off treatment as of analysis (14 disease progression, 4 adverse events (AEs), 4 other). One pt (4.5%) with prostate ca (PTEN deletion, MPRSS2-ERG fusion) attained a partial response (PR). Of 7 (32%) pts with stable disease (SD), 2 had SD > 6 months (uterine leiomyosarcoma; endometrial carcinoma). Of 54 pts with loss of PTEN protein by IHC (Arm P: 7 prostate, 6 breast, 3 squamous anal ca, 2 cholangiocarcinoma, 16 other), all are off treatment as of analysis (26 disease progression, 4 for AE, 4 other). Of 9 (37.5%) pts with SD, 3 had SD > 6 months (prostate cancer; squamous bladder cancer, squamous anal cancer). Median progression-free survival was 1.8 months for both arms. Gr ≥3 treatment-related (tr) reversible toxicities were experienced by 30% (7) of pts in arms N and P, respectively. No tr Gr 5 toxicities were observed in either arm.

Conclusions: Single agent GSK2636771 has very modest activity in ca with PTEN gene mutation/deletion and/or PTEN protein loss.

Clinical trial identification: NCT02465060.

Legal entity responsible for the study: NCI ECOG-ACRIN.

Funding: NCI ECOG-ACRIN.

Disclosure: F. Janku: Research support: Bristol-Myers Squibb, Novartis, Genentech, FujiFilm Pharmaceuticals, Plexxikon, Deciphera, Symphogen, Piqur, BioMed Valley Discoveries, and Upsher Smith Laboratories; Scientific Advisory Boards: Deciphera, Guardant Health, IFM Therapeutics; Consultant: Immunomet and Trovagen; Ownership interests: Trovagen. S.L. Puhalla: Consultant: AbbVie, MedImmune, Celldex, Puma, Pfizer, AstraZeneca, Esi, nanosting; Research funding to institution: AbbVie, Pfizer, Lilly, Novartis, Incyte, Covance-Bayer, AstraZeneca, Genentech, Medivation, P. Konstantinopoulos: Advisory boards; Pfizer, Merck and AstraZeneca. P.J. O’Dwyer: Research funding: GSK. All other authors have declared no conflicts of interest.